Metabolomics‐driven discovery of therapeutic targets for cancer cachexia
Journal of Cachexia, Sarcopenia and Muscle · 2024-06 · 15 (3) · 781-793
DOI: 10.1002/jcsm.13465 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 21.04.2024. Verfasst von Pengfei Cui und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Food and Pharmacy, Xuchang University, Xuchang, China. Hauptthemen laut MEDLINE: Cachexia, Metabolomics, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Foundation of Xuchang University, Education Department of Henan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer cachexia (CC) is a devastating metabolic syndrome characterized by skeletal muscle wasting and body weight loss, posing a significant burden on the health and survival of cancer patients. Despite ongoing efforts, effective treatments for CC are still lacking. Metabolomics, an advanced omics technique, offers a comprehensive analysis of small‐molecule metabolites involved in cellular metabolism. In CC research, metabolomics has emerged as a valuable tool for identifying diagnostic biomarkers, unravelling molecular mechanisms and discovering potential therapeutic targets. A comprehensive search strategy was implemented to retrieve relevant articles from primary databases, including Web of Science, Google Scholar, Scopus and PubMed, for CC and metabolomics. Recent advancements in metabolomics have deepened our understanding of CC by uncovering key metabolic signatures and elucidating underlying mechanisms. By targeting crucial metabolic pathways including glucose metabolism, amino acid metabolism, fatty acid metabolism, bile acid metabolism, ketone body metabolism, steroid metabolism and mitochondrial energy metabolism, it becomes possible to restore metabolic balance and alleviate CC symptoms. This review provides a comprehensive summary of metabolomics studies in CC, focusing on the discovery of potential therapeutic targets and the evaluation of modulating specific metabolic pathways for CC treatment. By harnessing the insights derived from metabolomics, novel interventions for CC can be developed, leading to improved patient outcomes and enhanced quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food and Pharmacy, Xuchang University, Xuchang, China.
- Xuchang Central Hospital, Xuchang, China.
- Research and Communication Center of Exercise and Health, Xiamen University of Technology, Xiamen, China.
- Key Laboratory for Chemical Biology of Fujian Province, MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, China.
ORCID-Profile: Donghai Lin
Förderung
- Scientific Research Foundation of Xuchang University
- Education Department of Henan Province
- National Natural Science Foundation of China
Zitieren
APA
Cui, P., Li, X., Huang, C., & Lin, D. (2024). Metabolomics‐driven discovery of therapeutic targets for cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 15(3), 781-793. https://doi.org/10.1002/jcsm.13465
Vancouver
Cui P, Li X, Huang C, Lin D. Metabolomics‐driven discovery of therapeutic targets for cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(3):781-793. doi:10.1002/jcsm.13465
BibTeX
@article{Cui2024,
author = {Cui, Pengfei and Li, Xiaoyi and Huang, Caihua and Lin, Donghai},
title = {Metabolomics‐driven discovery of therapeutic targets for cancer cachexia},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
volume = {15},
number = {3},
pages = {781--793},
doi = {10.1002/jcsm.13465}
}
EUVIMED